the role of mrd in the management of indolent nhl
Published 2 years ago • 68 plays • Length 7:13Download video MP4
Download video MP3
Similar videos
-
4:22
the role of mrd in aml
-
1:12
current role of mrd in aml
-
0:53
the current state of mrd in hodgkin lymphoma
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
0:44
the clinical meaning of mrd below the threshold of mcr in aml
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
3:24
treatment of bulky stage i/ii lymphoma
-
7:39
understanding mrd
-
3:07
minimal residual disease (mrd)
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
2:17
opinion: value of mrd as an endpoint in hem-onc clinical trials
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
2:42
the current role of chemotherapy in the treatment of hodgkin lymphoma & the impact of novel agents
-
1:30
advances in the management of r/r hodgkin lymphoma
-
2:06
understanding the role of inflammation and the immunome in mds pathophysiology
-
1:37
the role of ctdna in hodgkin lymphoma
-
1:35
update on phase i study of plamotamab in r/r nhl
-
2:03
novel therapeutic agents in the treatment of hodgkin and non-hodgkin lymphoma
-
0:50
mrd in the immuno-chemo era
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
3:07
the impact of blast enumeration & co-occurring myelodysplasia-related mutations in npm1-mutated aml